Cantor Fitzgerald Predicts Precigen FY2025 Earnings

Precigen, Inc. (NASDAQ:PGEN) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Precigen in a report issued on Thursday, March 20th. Cantor Fitzgerald analyst J. Kim anticipates that the biotechnology company will earn ($0.27) per share for the year. The consensus estimate for Precigen’s current full-year earnings is ($0.32) per share.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. Precigen had a negative net margin of 3,521.68% and a negative return on equity of 123.06%. The firm had revenue of $1.19 million during the quarter, compared to the consensus estimate of $1.30 million.

PGEN has been the subject of a number of other reports. HC Wainwright reiterated a “buy” rating and set a $6.00 price objective on shares of Precigen in a research note on Thursday, March 20th. JMP Securities reiterated a “market outperform” rating and issued a $5.00 price target on shares of Precigen in a research report on Tuesday, January 14th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Precigen Stock Performance

NASDAQ:PGEN opened at $1.71 on Monday. The stock has a 50-day simple moving average of $1.64 and a two-hundred day simple moving average of $1.17. The firm has a market capitalization of $502.81 million, a PE ratio of -3.11 and a beta of 1.58. Precigen has a 52-week low of $0.65 and a 52-week high of $2.17.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. State Street Corp raised its position in shares of Precigen by 1.0% during the third quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock valued at $2,720,000 after buying an additional 29,253 shares during the last quarter. LexAurum Advisors LLC increased its holdings in Precigen by 151.9% in the 4th quarter. LexAurum Advisors LLC now owns 691,544 shares of the biotechnology company’s stock valued at $775,000 after acquiring an additional 417,055 shares during the last quarter. Iridian Asset Management LLC CT increased its holdings in Precigen by 38.8% in the 4th quarter. Iridian Asset Management LLC CT now owns 5,241,922 shares of the biotechnology company’s stock valued at $5,871,000 after acquiring an additional 1,465,962 shares during the last quarter. Geode Capital Management LLC lifted its stake in Precigen by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock worth $3,075,000 after purchasing an additional 149,829 shares in the last quarter. Finally, Stifel Financial Corp boosted its holdings in shares of Precigen by 94.9% during the 3rd quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 15,680 shares during the last quarter. 33.51% of the stock is owned by hedge funds and other institutional investors.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.